Global Stem Cells Group will attend the world-class GTCbio conference at the Hyatt Regency Boston Hotel, April 27-29. The event will showcase the latest developments in all areas of regenerative medicine, stem cell research and business.
Global Stem Cells Group has announced plans to attend the GTCbio Stem Cell Summit 2015 April 27 – 29, 2015 in Boston. This world-class summit will present the latest developments in all areas of stem cell research including applications, biology, medicine, regulations, and the business of stem cells and regenerative medicine.
The conference will address recent developments in pre-clinical and clinical trials, as well as translational research in stem cell therapies, regenerative medicine, tissue engineering, stem cell reprogramming and regulatory guidance. There will be an additional focus on business opportunities in stem cell medicine and its challenges, and discussions on potential strategies for overcoming these challenges.
The GTCbio Summit includes two parallel conferences with joint sessions on stem cell research in the diabetes space, and stem cell therapies from bench to bedside. Both conferences will also feature a lineup of 34 distinguished speakers from a broad spectrum in the medical community. Keynote speakers for both conferences include Masayo Takahashi, MD, PhD, CDB Ophthalmologist, Center for Developmental Biology; Douglas Melton, PhD, Professor & Investigator, Harvard Medical School, and Rudolf Jaenisch, MD, Professor of Biology, Massachusetts Institute of Technology.
Conference A: The 12th Stem Cell Research & Regenerative Medicine Conference discussion topics include:
Cells for Therapeutic Development & Drug Discovery
Advances in Adult & Pluripotent Stem Cells
Tissue Engineering
Immunotherapy: Revolution in Cancer Treatments
Joint Session: Regulatory Challenges in Cell Therapy
Conference B: The 4th Stem Cell Product Development & Commercialization Conference discussion topics include:
Manufacturing & Product Development
Challenges in Developing Clinical Efficacy
Funding Opportunities
Commercialization: Creating Sustainable Business Models
Joint Session: Regulatory Challenges in Cell Therapy
The GTCbio Summit 2015 will be held at the Hyatt Regency Boston Hotel. For more information, visit the summit website. To learn more about Global Stem Cells Group, visit the GSCG website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.
Read More at: Official PR Release

Global Stem Cells Group has announced an exclusive representative contract with Chilean health management, development and biotechnology company Consortia Innovas, SA.
Global Stem Cells Group, Inc. has signed an exclusive representative contract with Consortia Innovas, SA, a Santiago, Chile-based health management, development and biotech company. Founded by entrepreneur Enrique Testart, M.D., Consortia Innovas focuses on helping patients gain access to the latest medical treatments regenerative medicine has to offer.
According to Global Stem Cells Group Founder Benito Novas, Testart searches the globe for innovative stem cell companies that fit in with the Chilean markets, and Global Stem Cells Group turned out to be a perfect fit. Innovas will be in charge of all Global Stem Cells Group divisions and programs in Chile, including patient recruiting through Cellgenic, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket.
Cellgenic, Stem Cell Training and Adimarket are all subsidiaries of the Global Stem Cells Group brand.
“Our main objective is to organize Chile’s first symposium on Stem Cells and Regenerative Medicine in Santiago in early 2015,” Novas says. “Our new alliance with Consortia Innovas will allow us to establish our brand as the leader in regenerative medicine therapies in Chile.”
The first annual Global Stem Cells Symposium is scheduled to take place in Buenos Aires Oct 2, 2014, to be preceded by an intensive two-day hands-on training course in stem cell harvesting, isolation and applications Sept. 27 and 28 at Santiago’s Innovas facilities.
The key to Global Stem Cells Group’s strategy to expand into foreign markets by recruiting local representatives and distributors like Consortia Innovas to help manage the company’s growth in a specific geographic area. Global Stem Cells group requires any company under consideration for the expansion program to have more than five years experience in the health care industry with at least some experience in the field of regenerative medicine .
In addition, geographic alliances require a commitment to a number of stem cell training courses during a one-year period, certification of physicians, and willingness to organize a large medical meeting or symposium in their territory.
About Consortia Innovas SA:
Consortia Innovas SA is comprised of a cluster of organizations designed to address the different needs of a new generation of consumers. With more than 20 years’ experience in the public and private sectors, Consortia Innovas specializes in designing customized B2B and B2C models for each central or regional organization, providing innovative services and diagnostic precision determined by local needs.
Consortia Innovas offers innovative and flexible technological and communication resources that enhance the skills of people in the management, operation and marketing fields. For more information, visit the Consortia Innovas SA website, Email contacto@innovas.cl, or call +56 2 2692 3650.

In conjunction with Regenerative Medicine Arroyo, Global Stem Cells Group has announced plans to hold a hands-on, intensive stem cell training course in Santa Cruz, Bolivia, April 4 and 5, 2015.
Global Stem Cells Group and its subsidiary, Stem Cells Training, has coordinated with Emil Arroyo, M.D. and Horacio Oliver, M.D. to conduct the first of four stem cell training courses planned for Bolivia in 2015. Devised to meet the increasing demand for regenerative medicine techniques in the region, the first adipose derived harvesting, isolation and re-integration training course will take place April 4 and 5, 2015, in Santa Cruz.
The two-day, hands-on intensive training course was developed for physicians and high-level practitioners to learn the techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow. The objective of the training is to provide physicians with practical stem cell medicine techniques they can use in-office to treat a variety of conditions in their patients.

Global Stem Cells Group will conduct a specialized course for qualified medical professionals on stem cell harvesting, isolation and re-integration on April 11, following the Congress on aesthetic medicine.
GlobalStemCellsGroup.com has announced plans to participate in the 25th annual Argentine Congress of Aesthetic Medicine April 9 and 10 2015. More than 1,000 physicians from around the world will descend on Buenos Aires for the conference to learn and share new findings in aesthetic medicine.
Following the congress, Global Stem Cells Group and Estanislao Janowski, M.D., a plastic surgeon specializing in stem cell application in aesthetic and cosmetic medicine will conduct an intensive, hands-on course on stem cell harvesting, isolation and re-integration, to be held April 11. Janowski, a GSCG faculty member and long-time collaborator is the owner and president of Bioplastica, an aesthetic surgical center featuring the latest stem cell applications in cosmetic and anti-aging medicine.
This will be the third year Global Stem Cells Group participates in the conference, hosted by the Argentina Society of Aesthetic Medicine (SOARME). A soon-to-be-named GSCG faculty member will also deliver a keynote speech to congress attendees.
The international event, which will be held at the Catholic University of Argentina in Buenos Aires, will feature acclaimed stem cell aesthetic practitioners from Argentina and the U.S. SOAME is a member of the Argentine Medical Association (A.M.A.) and of the International Union of Aesthetic Medicine (U.I.M.E.). SOAME has the scientific support of the John F. Kennedy University in Buenos Aires and a host of national and international scientific organizations.

The Global Stem Cells Group has established a collaborative alliance with HANK Bioengineering Co., Ltd. of Shenzhen, China.
Global Stem Cells Group.com has announced a newly formed alliance with Shenzhen HANK Bioengineering Co., Ltd. and its Chinese-American founder Mingjie Zhang, M.D., Ph.D. The alliance will establish a stem cells training course in the City of Shenzen, Guangdong Province, China in September 2015.
Shenzhen HANK is a biotechnology company established in 2013 by Zhang, an award-winning scientist, microbiologist and virologist, to integrate research, development, production, and sales of biomedical products. Zhang worked at the U.S. Centers for Disease Control from 1991 to 1993, the U.S. National Institute of Health (NIH) from 1993 to 1994, and the U.S. Food and Drug Administration from 1995 to 2013 in various research positions including National Research Center (NRC) senior associate from 1995 to 1997. In 2012 he earned the Scientific Achievement Award from the USFDA for outstanding achievement in natural killer (NK) cell research, and holds numerous awards for his work in the fields of HIV, HCV, West Nile virus, Japanese encephalitis virus, and quality performance.
In 2013, Dr. Zhang expanded on his work in stem cell research and development by launching HANK Bioengineering Co. Ltd. in Shenzhen, China. HANK is a 4,300 square foot (400 square meters) CFDA certified cGMP facility affiliated with HANK Bioengineering Institute’s Cell Biology and Molecular Immunology Laboratories. HANK has established close collaborations with more than five hospitals in China for clinical applications of its cell therapy products.
Shenzhen HANK is also a biotechnology service provider committed to the development and application of multiple immune cell therapy systems. The company has up to 20 cell therapy products of 4 series approved by the CFDA, including lymphocyte culture medium (NK, CTL and Treg cell in vitro culture reagents), lymphocyte serum-free culture medium, lymphocyte separation media, and lymphocyte freezing medium.
“Dr. Zhang and HANK Bioengineering will work seamlessly with our research, product development and education programs,” says Benito Novas, Global Stem Cells Group CEO. “This is a great opportunity for us to expand into China and work with one of the world’s most accomplished cell therapy researchers in his certified, cutting-edge cell biology laboratories.”

The Global Stem Cells Group has announced the addition of Biomedical Researcher Mario Camacho Alcocer to its faculty.
GlobalStemCellsGroup.com has recruited Mario Camacho Alcocer to the company’s growing faculty. Camacho Alcocer, a biomedical researcher and founding partner of Criogenix SA de CV in Queretaro, Mexico, will join GSCG’s team of biomedical professors who will teach the “Diplomat in Cell Therapy and Tissue Engineering” program.
Criogenix SA de CV is a private company registered in the National Record of Scientific and Technological Institutions and Companies in Mexico (RENIECYT).
Camacho Alcocer will teach two-day, interactive training courses on adult stem cell extraction and re-integration to physicians and qualified medical practitioners who wish to learn and use the process in their practices.
Camacho Alcocer is accomplished in generating and applying new stem cell therapeutic protocols and technologies. His current research focuses on extracellular matrix interactions to regulate the dynamic of defined stem cells populations, with a goal to regenerate functional capabilities of specific tissues (or to develop tissues in vitro), as well as the development of specific scaffolds for cell culture. His research is central to Criogenix SA de CV’s development of a major integral stem cell unit management system for therapeutic applications.
Global Stem Cells Group and StemCell Center are expanding the company’s clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Cellgenic banner.
In 2014, Global Stem Cells Group expanded its StemCell Center’s global presence to 20 countries. Cellgenic offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide.
Cellgenic is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Cellgenic clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.
The Global Stem Cells Group is committed to the highest standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

Global Stem Cells Group and Cellgenic announce the launch of two new kits for physicians to use in isolating and harvesting stem cells from bone marrow and adipose tissue based on Adistem technology.
In answer to industry-wide requests for more accessible solutions to stem cell procedures, Global Stem Cells Group, Inc. and Cellgenic have announced the launch of two new stem cell harvesting and isolation kits.
The Cellgenic BMAC 60 mL concentrating system is a high performing concentrating system for bone marrow aspirate. This kit come complete with a bone marrow filter, a bone marrow aspirating needle and a locking syringe to help maintain suction during the aspirating process. The BMAC 60 kit includes bone marrow concentrate up to 11 times the baseline values, to produce 6-8 mL BMC from a 60 mL sample of bone marrow aspirate.
The Cellgenic 60 mL Adipose Derived Stem Cell (ADSC) Kit System includes all the tools and consumables for the extraction of adipose-derived stem cells from 60 mL of lipoaspirated fat. The ADSC kit is currently being used in clinical procedures for lung disease, intra-articular injections for osteoarthritis of the knee and hip, cosmetic surgery and acne scarring, dermal injections, stem cell enriched fat transfer, wounds, chronic ulcers and other chronic conditions. The enzymatic component used to obtain the stromal vascular fraction (SVF) is provided by Adistem.
The Cellgenic ADSC Kit System is available in three versions:
Gold, to conduct in-office stem cell procedures with certified GMP components for reliable performance.
Platinum, with all the benefits of the basic (gold) kit plus a sterilized PRP close system with vortex engineering method to minimize platelet loss. One set of individually packed Tulip Gems instruments are added for safe and precise adipose tissue extraction.
Titanium, the perfect state-of-the-art deluxe kit system used by a growing number of regenerative medicine physicians and recognized as the perfect preparation for virtually all clinical applications. Built with Emcyte technology, the Cellgenic Titanium kit has been independently reviewed and proven in various critical performance points that make a difference in patient outcomes.
The Titanium kit is currently being used in topical procedures such as intra-articular injection for osteoarthritis of the knee and hip, cosmetic surgery and acne scarring, dermal injection, stem cell enriched fat transfer, wounds chronic ulcers among other chronic conditions.
According to Global Stem Cells Group CEO Benito Novas, the entire Global Stem Cells Group faculty and scientific advisory board worked together to develop the kits.
“These new products will help us carry out our mission to provide accessible GMP certified kits to our member client, ensuring that more patients will be able to gain access to these therapies,” says Novas. “We are confident that the regenerative medicine industry will be excited to receive these products.”
About Adistem:
AdiStem Ltd. is a provider of photo-activation technology and medical solutions that assist in orthopedic, cosmetic, neurologic, pulmonary, metabolic and plastic/reconstructive surgery procedures.
The company owns proprietary technology for PRP procedures and for autologous adult adipose-derived stem cell isolation and administration. The use of AdiLight-2 for the photo activation of PRP requires no training. On the other hand, the adult stem cell technology is shared with qualified clinicians through instructional courses, workshops and seminars.
AdiStem has also isolated specific biomolecules from autologous adult adipose-derived stem cells that target a number of chronic diseases including HIV/Aids, pain, and Type II diabetes.

Global Stem Cells Group announced that it has signed a memorandum of understanding with the Regenerative Technology Alliance (RTA) to evaluate and promote stem cell training programs.
Global Stem Cells Group and the Regenerative Technology Alliance (RTA) have signed a memorandum of understanding to evaluate and promote stem cell training programs. RTA, a global provider of standards and certification for the emerging fields of regenerative medicine and science, will work with the Global Stem Cells Group to evaluate the regenerative medicine company’s training programs and assess GSCG’s participating physicians against the RTA’s established international standards for the practice of regenerative and cell-based medicine.
“Our new alliance with the RTA is a natural step toward establishing GSCG’s recognition as a global leader in stem cell medicine,” says Global Stem Cells Group CEO Benito Novas. “This is a perfect fit for us, as Global Stem Cells Group shares the RTA’s focus on high standards and transparency, especially when it comes to patient safety and advancing the field of stem cell medicine.”
“We are very pleased to have this alliance,” says David Audley, General Secretary and Chair of the RTA. “Our goal is to provide the highest level of transparency and oversight for the industry. Working with Global will allow us to have a direct and dramatic impact on physician training.”
About the RTA
The Regenerative Technology Alliance (RTA) a global provider of standards and certification for the emerging fields of regenerative medicine and science, is a 501(c)3 and is supported by donations from individuals, corporations and foundations to help advance its critical mission of bringing peer oversight and transparency to the field of cell-based and regenerative medicine.

Global Stem Cells Group has announced an agreement to share protocols with Advancells, a pioneer stem cell company that provides a range of safe treatments for various diseases. The alliance will also pave the way for Global Stem Cells Group to expand operations in India.
Global Stem Cells Group, Inc. announced an alliance with India-based stem cells company Advancells.com, to share protocols and expand GSCG operations in the India subcontinent with stem cell training and a new treatment center.
Advancells, a pioneer stem cell company with some of the most advanced protocols in the world, focuses on therapeutic applications of regenerative medicine primarily used in stem cells generated from the patient’s own body. Advancells delivers technologies for safe and effective treatments using their flagship technologies including autologous stem cell therapy from bone marrow and adipose tissue to patients worldwide; Global Stem Cells Group will implement some Advancells technologies in the StemCell Center of worldwide clinics.
Since 2005, Advancells has safely treated thousands of patients for a range of diseases and medical conditions in its various clinics around the globe. Advancells is supported by physicians, stem cell experts and clinical research scientists to continually monitor and improve the effectiveness of its quality management system with excellence and innovation.
“We are pleased to partner with Global Stem Cells Group, to combine our knowledge and expand our ability to bring stem cell medicine to patients worldwide,” says Advancells CEO Vipul Jain. “I am looking forward to a long and productive alliance.”
For more information, visit the Global Stem Cells Group website, email bnovas(AT)stemcellsgroup.com, or call 305-560-5337.
About Advancells:
Advancells is focused on the therapeutic applications of regenerative medicine primarily used in stem cells generated from the patient’s own body. Using technologies like autologous stem cell therapy from bone marrow and adipose tissue, Advancells has been successfully treating patients on a global level since 2005. The company strives to maintain scientific and ethical traditions through Good Manufacturing Practices in accordance with the accepted national and international norms.